// App-Quantinova.ai

: Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Researchers

Presenter

  • Hany Elmariah

Principal Investigators

  • Ambuj Kumar

  • Haris Ali

  • Shukaib Arslan

  • Amrita Desai

  • Amanda Blackmon

  • Hoda Pourhassan

  • Taiga Nishihori

  • Rawan Faramand

  • Asmita Mishra

  • Farhad Khimani

  • Hugo F Fernandez

  • Aleksandr Lazaryan

  • Michael Nieder

  • Lia Perez

  • Hien D. Liu

  • Ryotaro Nakamura

  • Joseph Pidala

  • Guido Marcucci

  • Stephen J Forman

  • Claudio Anasetti

  • Frederick L. Locke

  • Nelli Bejanyan

  • Monzr M. Al Malki

Medical Centers

  • Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

  • Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Pembroke Pines

  • Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

  • Morsani College of Medicine, University of South Florida, Tampa, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Hematological malignancies

  • Solid malignancies

  • Graft-versus-host disease

Biomarkers

  • Hematocrit

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Tacrolimus

  • sirolimus

  • Rapacan

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved